Related references
Note: Only part of the references are listed.Midbrain D3 Receptor Availability Predicts Escalation in Cocaine Self-administration
Stephanie M. Groman et al.
BIOLOGICAL PSYCHIATRY (2020)
The highly selective dopamine D3R antagonist, R-VK4-40 attenuates oxycodone reward and augments analgesia in rodents
Chloe J. Jordan et al.
NEUROPHARMACOLOGY (2019)
Treatment-resistant and multi-therapy-resistant criteria for bipolar depression: consensus definition
Diego Hidalgo-Mazzei et al.
BRITISH JOURNAL OF PSYCHIATRY (2019)
The Dopamine Receptor D3 Regulates Lipopolysaccharide-Induced Depressive-Like Behavior in Mice
Jing Wang et al.
INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY (2018)
Reward motivation in humans and its relationship to dopamine D2/3 receptor availability: A pilot study with dual [11C]-raclopride and [11C]-(+)-PHNO imaging
Fernando Caravaggio et al.
JOURNAL OF PSYCHOPHARMACOLOGY (2018)
Efficacy and safety of pramipexole extended-release in Parkinson's disease: a review based on meta-analysis of randomized controlled trials
T. Shen et al.
EUROPEAN JOURNAL OF NEUROLOGY (2017)
Psychometric validation of a multi-dimensional capability instrument for outcome measurement in mental health research (OxCAP-MH)
Francis Vergunst et al.
HEALTH AND QUALITY OF LIFE OUTCOMES (2017)
The dopamine hypothesis of bipolar affective disorder: the state of the art and implications for treatment
A. H. Ashok et al.
MOLECULAR PSYCHIATRY (2017)
Assessing the validity of the ICECAP-A capability measure for adults with depression
Paul Mark Mitchell et al.
BMC PSYCHIATRY (2017)
Clinical Experience With High-Dosage Pramipexole in Patients With Treatment-Resistant Depressive Episodes in Unipolar and Bipolar Depression
Jan Fawcett et al.
AMERICAN JOURNAL OF PSYCHIATRY (2016)
Evidence-based guidelines for treating bipolar disorder: Revised third edition recommendations from the British Association for Psychopharmacology
G. M. Goodwin et al.
JOURNAL OF PSYCHOPHARMACOLOGY (2016)
Occupancy of pramipexole (Sifrol) at cerebral dopamine D2/3 receptors in Parkinson's disease patients
Angela Deutschlaender et al.
NEUROIMAGE-CLINICAL (2016)
Comparative evaluation of quetiapine plus lamotrigine combination versus quetiapine monotherapy (and folic acid versus placebo) in bipolar depression (CEQUEL): a 2 x 2 factorial randomised trial
John R. Geddes et al.
LANCET PSYCHIATRY (2016)
Life expectancy in bipolar disorder
Lars Vedel Kessing et al.
BIPOLAR DISORDERS (2015)
Hippocampal Neurogenesis, Neurotrophic Factors and Depression: Possible Therapeutic Targets?
Gianluca Serafini et al.
CNS & Neurological Disorders-Drug Targets (2015)
Long-term treatment with L-DOPA or pramipexole affects adult neurogenesis and corresponding non-motor behavior in a mouse model of Parkinson's disease
W. -H. Chiu et al.
NEUROPHARMACOLOGY (2015)
Bipolar disorder prevalence: a systematic review and meta-analysis of the literature
Adauto S. Clemente et al.
REVISTA BRASILEIRA DE PSIQUIATRIA (2015)
SCORING THE ICECAP-A CAPABILITY INSTRUMENT. ESTIMATION OF A UK GENERAL POPULATION TARIFF
Terry N. Flynn et al.
HEALTH ECONOMICS (2015)
Dopamine receptor D3 deficiency results in chronic depression and anxiety
Rodrigo Moraga-Amaro et al.
BEHAVIOURAL BRAIN RESEARCH (2014)
Superior chronic tolerability of adjunctive modafinil compared to pramipexole in treatment-resistant bipolar disorder
Bernardo Dell'Osso et al.
JOURNAL OF AFFECTIVE DISORDERS (2013)
Questionnaire for impulsive-compulsive disorders in Parkinson's Disease-Rating Scale
Daniel Weintraub et al.
MOVEMENT DISORDERS (2012)
The Efficacy of Pramipexole, a Dopamine Receptor Agonist, as an Adjunctive Treatment in Treatment-Resistant Depression: An Open-Label Trial
Hiroaki Hori et al.
SCIENTIFIC WORLD JOURNAL (2012)
Annual cost of managing bipolar disorder to the UK healthcare system
Allan H. Young et al.
JOURNAL OF AFFECTIVE DISORDERS (2011)
Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L)
M. Herdman et al.
QUALITY OF LIFE RESEARCH (2011)
Lithium plus valproate combination therapy versus monotherapy for relapse prevention in bipolar I disorder (BALANCE): a randomised open-label trial
John R. Geddes et al.
LANCET (2010)
Pramipexole for the treatment of depressive symptoms in patients with Parkinson's disease: a randomised, double-blind, placebo-controlled trial
Paolo Barone et al.
LANCET NEUROLOGY (2010)
Long-Term Use of Pramipexole in Bipolar Depression: A Naturalistic Retrospective Chart Review
Rif S. El-Mallakh et al.
PSYCHIATRIC QUARTERLY (2010)
The Effect of Pramipexole on Mood and Motivational Symptoms in Parkinson's Disease: A Meta-analysis of Placebo-Controlled Studies
Albert F. G. Leentjens et al.
CLINICAL THERAPEUTICS (2009)
Antidepressant effects of pramipexole, a dopamine D3/D2 receptor agonist, and 7-OH-DPAT, a dopamine D3 receptor agonist, in olfactory bulbectomized rats
Megan E. Breuer et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2009)
Effects of pramipexole on the duration of immobility during the forced swim test in normal and ACTH-treated rats
Kouhei Kitagawa et al.
NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY (2009)
A brief measure for assessing generalized anxiety disorder -: The GAD-7
Robert L. Spitzer et al.
ARCHIVES OF INTERNAL MEDICINE (2006)
Cost-of-illness analysis - What room in health economics?
R Tarricone
HEALTH POLICY (2006)
A randomized, double-blind, placebo-controlled trial of quetiapine in the treatment of bipolar I or II depression
JR Calabrese et al.
AMERICAN JOURNAL OF PSYCHIATRY (2005)
Preliminary randomized, double-blind, placebo-controlled trial of pramipexole added to mood stabilizers for treatment-resistant bipolar depression
JF Goldberg et al.
AMERICAN JOURNAL OF PSYCHIATRY (2004)
Pramipexole for bipolar II depression: A placebo-controlled proof of concept study
CA Zarate et al.
BIOLOGICAL PSYCHIATRY (2004)
The 16-item Quick Inventory of Depressive Symptomatology (QIDS), clinician rating (QIDS-C), and self-report (QIDS-SR): A psychometric evaluation in patients with chronic major depression
AJ Rush et al.
BIOLOGICAL PSYCHIATRY (2003)
A prospective investigation of the natural history of the long-term weekly symptomatic status of bipolar II disorder
LL Judd et al.
ARCHIVES OF GENERAL PSYCHIATRY (2003)
Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression
M Tohen et al.
ARCHIVES OF GENERAL PSYCHIATRY (2003)
Pramipexole in treatment-resistant depression: a 16-week naturalistic study
L Lattanzi et al.
BIPOLAR DISORDERS (2002)
The long-term natural history of the weekly symptomatic status of bipolar I disorder
LL Judd et al.
ARCHIVES OF GENERAL PSYCHIATRY (2002)
The Work and Social Adjustment Scale: a simple measure of impairment in functioning
JC Mundt et al.
BRITISH JOURNAL OF PSYCHIATRY (2002)
Regulation of adult neurogenesis by antidepressant treatment
RS Duman et al.
NEUROPSYCHOPHARMACOLOGY (2001)
Adjunctive dopamine agonists in treatment-resistant bipolar II depression: an open case series
G Perugi et al.
PHARMACOPSYCHIATRY (2001)
Stabilization in the treatment of mania, depression and mixed states
DJ Kupfer et al.
ACTA NEUROPSYCHIATRICA (2000)
Share Paper
